Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

3 Health Care Stock Under $50 You Can Buy Today

The healthcare industry is anticipated to grow significantly in the coming years, thanks to strong demand amid rising chronic diseases, technological advancements, and rising healthcare spending. Therefore, we think fundamentally sound healthcare companies Pfizer (PFE), GSK Plc (GSK), and Teva Pharmaceutical (TEVA), which are currently trading under $50, could be…

StockNews.com

German firm DFE Pharma’s CoE opened in Genome Valley

‘Capabilities offered through this centre can reduce the time to launch a product’

The Hindu

Cannabis Company Tilray Just Made a Major Blunder

A Tilray press release last week seems to have caused some dismay among Germany's drug regulators.

The Street

From analysis to the latest developments in health,
read the most diverse news in one place.

Cannabis-based medicine approved for use in Scotland for those living with MS

A CANNABIS-BASED medicine has been approved for use for people living with multiple sclerosis (MS) in Scotland.

The National (Scotland)

EU watchdog approves vaccine targeting Omicron sub-variants

The Hague (AFP) - The EU's medicines watchdog on Monday approved a vaccine specifically targeting the new and contagious types of the Omicron variant amid fears of a new wave of Covid-19 winter infections.

AFP

Biden promotes US biotech, cancer fight in new 'Moonshot'

Boston (AFP) - President Joe Biden issued an executive order Monday boosting the US biotech sector as part of his Cancer Moonshot initiative, which invokes the national effort to land a man on the Moon 60 years ago.

AFP

EU Regulator Backs Pfizer's BA.4/5-Adapted COVID Booster

The European Medicines Agency (EMA) on Monday recommended a COVID-19 booster designed to combat Omicron offshoots BA.4/5, days after endorsing a pair of boosters tailored to target the older BA.1 variant. The latest recommendation is for a so-called bivalent vaccine developed by Pfizer and BioNTech, which targets BA.4/5 as well…

Asharq Al-Awsat

Read news from The Economist, FT, and more,
with one subscription

Bristol Myers Squibb Stock: Here's the Key Breakout Level to Watch

Bristol Myers Squibb received good news from the FDA, but only enough to put a key resistance level in play. Here's the level it needs to clear.

The Street

EU regulator clears Pfizer-BioNTech's tweaked COVID booster

The European Medicines Agency has recommended the authorization of a tweaked booster dose of the Pfizer-BioNTech coronavirus vaccine that includes protection against two of the latest versions of omicron, as countries look to bolster their immunization programs ahead of winter

The Independent UK

Johnson Johnson Will Pay $300M To Women Who’ve Suffered From Pelvic Mesh Implant Complications

The settlement will help cover women's ongoing treatment for injuries caused by the mesh implants.

Pedestrian.tv

Bristol Myers Stock Surges After FDA Approves New Plaque Psoriasis Treatment; Amgen Slides

“We believe Sotyktu is a breakthrough in the treatment of patients suffering from moderate-to-severe plaque psoriasis," said Bristol Myers' chief medical officer Samit Hirawat.

The Street

Biden to announce new support for US biotech production

President Joe Biden is announcing a new initiative to encourage biotech production and research in the U.S. It's the latest move by the White House to boost domestic industry

The Independent UK

Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ (NASDAQ:SPPI) lead asset ROLVEDON (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia. Spectrum Pharmaceuticals shares traded as high as 3.17 percent, in a range of $1.21 to $1.30 on day volume of 6.8 million…

Benzinga

Juul just lost a big battle

The e-cigarette company was being investigated by more than 30 states for allegedly marketing its products to youth

Salon

Get all your
news in one place.

100’s of premium titles.
One news app.

The Street

Regeneron's Eylea Win Leaves an Elephant in the Room

Regeneron's Eylea eye-disorder drug faces competitive pressure on multiple fronts. New data could cement its dominance.

The Street

A Longer-Acting Botox Competitor is Coming

Revance Therapeutics claimed FDA approval for Daxxify. Ramping sales will take years.

The Street

There's a New Way to Get Rid of Wrinkles

Botox's dominance of the facial injections market is facing new competition.

Los Angeles Times

Michael Hiltzik: This life-saving drug will cost a record $2.8 million. Who will pay the price?

For the estimated 1,500 Americans suffering from a blood disorder known as beta thalassemia, the Food and Drug Administration's approval Aug. 17 of the drug Zynteglo was almost unalloyed good news.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Junshi Biosciences Hits Revenue Roadblock Amid Covid Drug Delay

Key Takeaways: The company logged a revenue fall of 55% in the first half of the year and posted a loss of $131 million Phase 3 clinical trials for its Covid-19 oral drug wrapped up in May but the company has still not yet filed an application to market the…

The Hindu

Zenara launches generic version of Pfizer Covid drug Paxlovid

Sets MRP at ₹5,200 for a box of 20 Nirmatrelvir tablets, 10 tablets of Ritonavir

Bangkok Post

IRPC preparing to buy speciality polymer assets

IRPC, the petrochemical arm of national oil and gas conglomerate PTT Plc, is preparing to buy new assets in the speciality polymer manufacturing segment as it steps up efforts to earn more revenue from high-margin products.

The Street

FDA Faces a Tough Call - and Again Risks Its Credibility

Another controversial neuroscience drug could soon be approved.

Benzinga

Trump Ally Dr. Oz Hyped Unapproved 'Covid Cures' From Companies He Owns Shares Of

Republican Pennsylvania Senate candidate Dr. Mehmet Oz owns shares of two companies he publicly supported, touting their drugs as potential Covid-19 treatments — even though the drugs weren't approved by the U.S. Food and Drug Administration (FDA).

Birmingham Post

Losses widen at Shield Therapeutics though sales and prescriptions of its drugs grow

The maker of iron deficiency tablets says there is a huge unmet need for its products in the US were about 20 million people suffer anaemia

Benzinga

Canadian Psychedelics Company Reduces Manufacturing Time Of MDMA By Two Thirds

Nirvana Life Sciences Inc. (CSE: NIRV) announced that it has engineered a method that reduces the manufacturing time of MDMA by two thirds.

1 … 128 129 130 131

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.